Instead of disclosing the results from all 15 ALS patients enrolled in Neuralstem's phase II study of NSI-566, the company decided to only release a comparison between the patients who responded and those who didn't respond. Of course, the seven responders in the study showed more stabilization or improvements in muscle function compared to the eight patients deemed non-responders.
http://ift.tt/1B8Ootq
http://ift.tt/1B8Ootq
No comments:
Post a Comment